Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.

Abstract

BACKGROUND/AIMS:

Cancer stem cells (CSCs) are largely responsible for tumor relapse and metastatic behavior. Doublecortin-like kinase 1 (DCLK1) was recently reported to be a biomarker for gastrointestinal CSCs and involved in the epithelial-mesenchymal transition (EMT) and tumor progression. B cell-specific Moloney murine leukemia virus insertion site 1 (Bmi-1) is a crucial regulator of CSC self-renewal, malignant transformation and EMT, and a previous study from our group showed that Bmi-1 is upregulated in pancreatic cancer progression and participates in EMT. However, it remains unclear whether DCLK1 is involved in pancreatic cancer or whether DCLK1 is associated with the altered level of Bmi-1 expression.

METHODS:

The correlation of DCLK1 expression and clinical features of pancreatic cancer was analyzed in 210 paraffin-embedded archived pancreatic cancer specimens by immunohistochemical analysis. The biological effects of DCLK1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays, cell migration by wound healing assay and cell invasion by Transwell invasion assay. We further investigated the effect of therapeutic siRNA targeting DCLK1 on pancreatic cancer cell growth in vivo. Moreover, the molecular mechanism by which DCLK1 upregulates Bmi-1 expression was explored using real-time PCR, western blotting and Co-immunoprecipitation assay.

RESULTS:

DCLK1 is overexpressed in pancreatic cancer and is related to metastasis and prognosis. Knockdown of DCLK1 markedly suppressed cell growth in vitro and in vivo and also inhibited the migration and invasion of pancreatic cancer cells. Furthermore, we found that DCLK1 silencing could inhibit EMT in cancer cells via downregulation of Bmi-1 and the mesenchymal markers Snail and Vimentin and upregulation of the epithelial marker E-cadherin. Moreover, high DCLK1 expression in human pancreatic cancer samples was associated with a mesenchymal phenotype and increased cell proliferation. Further co-immunoprecipitation indicated that DCLK1 did not interact with Bmi-1 directly.

CONCLUSION:

Our data suggest that upregulation of DCLK1 may contribute to pancreatic cancer metastasis and poor prognosis by increasing Bmi-1 expression indirectly. The findings indicate that inhibiting DCLK1 expression might be a novel strategy for pancreatic cancer therapy.

• Authors: Jian Li, Yunchao Wang, Jiayun Ge, Wenhua Li, Liangyu Yin, Zhiping Zhao, Songsong Liu, Huan Qin, Jiali Yang, Lijiang Wang, Bing Ni, Yongkang Liu, Huaizhi Wang
• Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology (Cell Physiol Biochem) Vol. 51 Issue 1 Pg. 262-277 ( 2018) ISSN: 1421-9778 [Electronic] Germany
• PMID: 30453285 (Publication Type: Journal Article)
• Copyright: © 2018 The Author(s). Published by S. Karger AG, Basel.

Chemical References

• BMI1 protein, human
• Cadherins
• Intracellular Signaling Peptides and Proteins
• RNA, Small Interfering
• Snail Family Transcription Factors
• Vimentin
• Polycomb Repressive Complex 1
• DCLK1 protein, human
• Doublecortin-Like Kinases
• Protein Serine-Threonine Kinases

Topics

• Animals
• Cadherins (metabolism)
• Cell Line, Tumor
• Cell Movement
• Cell Proliferation
• Doublecortin-Like Kinases
• Epithelial-Mesenchymal Transition
• Gene Expression Regulation
• Humans
• Intracellular Signaling Peptides and Proteins (antagonists & inhibitors, genetics, metabolism)
• Kaplan-Meier Estimate
• Mice
• Mice, Nude
• Neoplastic Stem Cells (cytology, metabolism)
• Pancreatic Neoplasms (drug therapy, mortality, pathology)
• Polycomb Repressive Complex 1 (metabolism)
• Prognosis
• Protein Serine-Threonine Kinases (antagonists & inhibitors, genetics, metabolism)
• RNA Interference
• RNA, Small Interfering (metabolism, therapeutic use)
• Snail Family Transcription Factors (metabolism)
• Vimentin (metabolism)